Benitrobenrazide

Benitrobenrazide (BNBZ) is the orally active inhibitor for hexokinase 2 with an IC50 of 0.53 µM. Benitrobenrazide causes DNA damage, and exhibits antitumor effect[1][2].

Product Specifications

CAS Number

[2454676-05-0]

Product Name Alternative

BNBZ; Hexokinase 2 inhibitor 1

UNSPSC

12352005

Target

Apoptosis; Hexokinase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hexokinase-2-inhibitor-1.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N/N=C/C1=CC=C(O)C(O)=C1O)C2=CC=C([N+]([O-])=O)C=C2

Molecular Formula

C14H11N3O6

Molecular Weight

317.25

References & Citations

[1]Juszczak K, et al. Hexokinase 2 Inhibition and Biological Effects of BNBZ and Its Derivatives: The Influence of the Number and Arrangement of Hydroxyl Groups. Int J Mol Sci. 2022 Feb 27;23 (5) :2616.|[2]Zheng M, et al., Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis. Pharmacol Res. 2021 Feb;164:105367.